Recent Developments in Adaptive Designs for Phase I/II Dose-Finding Studies
- 8 November 2007
- journal article
- research article
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 17 (6) , 1071-1083
Abstract
Cancer dose-finding trials aim at assessing the maximum tolerated dose (MTD) of a new treatment or combination. Owing to ethical constraint, they are based on adaptive designs, sequentially allocating patients to increased doses on the basis of previous responses. More recently, the concept of MTD has been extended to the largest concept of most successful or most desirable dose, based on efficacy criterion under toxicity restrictions. The aim of this paper is to present three main approaches proposed to estimate such a dose, in the setting of Phase I/II trials. Two case-studies allow to illustrate these new approaches.Keywords
This publication has 17 references indexed in Scilit:
- Adaptive Dose Selection Using Efficacy-Toxicity Trade-Offs: Illustrations and Practical ConsiderationsJournal of Biopharmaceutical Statistics, 2006
- Optimal designs for estimating the most successful doseStatistics in Medicine, 2006
- A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemiaBritish Journal of Cancer, 2006
- Adaptive designs for dose-finding based on efficacy–toxicity responseJournal of Statistical Planning and Inference, 2006
- Identifying the most successful dose (MSD) in dose‐finding studies in cancerPharmaceutical Statistics, 2006
- Bayesian Dose‐Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds RatiosBiometrics, 2006
- Bayesian decision procedures for dose‐escalation based on evidence of undesirable events and therapeutic benefitStatistics in Medicine, 2005
- A Bayesian dose finding design for dual endpoint phase I trialsStatistics in Medicine, 2005
- A Bayesian Approach to Jointly Modeling Toxicity and Biomarker Expression in a Phase I/II Dose‐Finding TrialBiometrics, 2005
- Dose‐Finding Based on Efficacy–Toxicity Trade‐OffsBiometrics, 2004